AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Saniona Share Issue/Capital Change 2020

Mar 11, 2020

3195_rns_2020-03-11_a9b7f4f3-3b09-4b4b-aa10-ee8b07b462f0.pdf

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

saniona

PRESS RELEASE

March 11, 2020

Saniona’s announces last day of trading in BTU and first day of trading in warrants of series TO 1, TO 2 and TO 3

Saniona AB’s rights issue of units has been registered with the Swedish Companies Registration Office. The last day for trading in paid subscription units (“BTU”) is March 17th, 2020. Euroclear’s record date for conversion from BTU to warrants is March 19th, 2020. The new warrants are expected to be distributed to the respective shareholder’s VP account/depot on March 23rd, 2020. First day of trading in the warrants (TO 1, TO 2 and TO 3) on Nasdaq Stockholm is expected to be March 23rd, 2020.

For more information, please contact

Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: [email protected]

The information was submitted for publication, through the agency of the contact person set out above, at 2.30 p.m./p.m. CET on March 11, 2020.

About Saniona

Saniona (OMX: SANION) focuses on research and development of drugs to treat rare diseases of the central nervous system. Saniona intends to independently develop and commercialize treatments for orphan indications such as Prader-Willi syndrome and hypothalamic obesity. The company currently has three proprietary programs in clinical development and four clinical development programs in partnership. Saniona’s drug discovery platform is focused on ion channel research and the company has a broad portfolio of early stage programs. Saniona’s partners include Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics.